Highlights Cantargia AB

Equities

CANTA

SE0006371126

Market Closed - Nasdaq Stockholm Other stock markets 06:59:40 2024-04-30 am EDT			5-day change	1st Jan Change
3.336 ^SEK	-2.74%		-10.56%	-10.75%

Apr. 17	Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	CI
Apr. 10	Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	Apr. 17	CI
Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	Apr. 10	CI
Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer	Apr. 08	CI
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis	Apr. 02	CI
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia	Mar. 27	CI
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis	Mar. 14	CI
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer	Mar. 05	CI
Cantargia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab	Feb. 20	CI
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy	Feb. 12	CI
Cantargia Reports Phase I Clinical Progress in the CAN10 Project	Jan. 09	CI
Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10	Nov. 24	CI
Cantargia Maintains Patent for Cancer Treatment Amid Withdrawal of Third-party Appeal	Nov. 20	MT
Cantargia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer	23-09-27	CI
Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR	23-09-20	CI
Cantargia AB Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant	23-09-18	CI
Cantargia ABExpands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases	23-09-05	CI
Cantargia AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
Cantargia AB Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10	23-08-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cantargia AB

Equities

CANTA

SE0006371126

Highlights

Filters